Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Bioequivalence Study of Paricalcitol Capsules, 4 mcg Under Fasting Conditions

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02322632
Recruitment Status : Completed
First Posted : December 23, 2014
Last Update Posted : December 23, 2014
Sponsor:
Information provided by (Responsible Party):
Dr. Reddy's Laboratories Limited

Brief Summary:
An open-label, balanced, randomized, two-treatment, two-sequence, two-period, single-dose, crossover oral bioequivalence study in healthy subjects under fasting conditions.

Condition or disease Intervention/treatment Phase
Healthy Drug: Paricalcitol Capsules, 4 mcg Phase 1

Detailed Description:
An open-label, balanced, randomized, two-treatment, two-sequence, two-period, single-dose, crossover oral bioequivalence study of Paricalcitol Capsules 4 mcg of Dr. Reddy's Laboratories Limited and Zemplar® Capsules 4 mcg of Abbott Laboratories, USA in healthy, adult, human subjects under fasting conditions.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 69 participants
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: An Open-label, Balanced, Randomized, Two-treatment, Two-sequence, Two-period, Single-dose, Crossover Oral Bioequivalence Study of Paricalcitol Capsules 4 mcg of Dr. Reddy's Laboratories Limited and Zemplar Capsules, 4 mcg of Abbott Laboratories, USA in Healthy, Adult, Human Subjects Under Fasting Conditions.
Study Start Date : November 2010
Actual Primary Completion Date : December 2010
Actual Study Completion Date : February 2011

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: Paricalcitol Capsules, 4 mcg
Paricalcitol Capsules, 4 mcg of Dr. Reddy's Laboratories Limited
Drug: Paricalcitol Capsules, 4 mcg
Paricalcitol Capsules, 4 mcg of Dr. Reddy's Laboratories Limited
Other Name: Zemplar

Experimental: Zemplar Capsules, 4 mcg
Zemplar Capsules, 4 mcg of Abott Laboratories USA
Drug: Paricalcitol Capsules, 4 mcg
Paricalcitol Capsules, 4 mcg of Dr. Reddy's Laboratories Limited
Other Name: Zemplar




Primary Outcome Measures :
  1. Area under curve [ Time Frame: 0.25, 0.5, 0.75, 1.0, 1.25, 1.5, 1.75, 2.0, 2.5, 3.0, 3.5, 4.0, 6.0, 8.0, 10.0, 12.0, 16.0, 24.0, 36.0, 48.0 and 60.0 hours post-dose ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 55 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Healthy, adult, human volunteers between 18 and 55 years of age (both inclusive) living in and around Ahmedabad city of western part of India.
  • Having a Body Mass Index (BMI) between 18.5 and 24.9 (both inclusive), calculated as weight in kg/height in m2.
  • Have no significant diseases or clinically significant abnormal findings during screening, medical history, clinical examination, laboratory evaluations, 12- lead ECG and X-ray chest (postero-anterior view) recordings.
  • Volunteers who have normal calcium, phosphorous status and no hypertensive status in order to avoid effect on vitamin D concentration in blood.
  • Able to comply with the study procedures, in the opinion of the Principal investigator.
  • Able to give voluntary informed consent for participation in the trial.

In case of female subjects*:

  • Surgically sterilized at least 6 months prior to study participation; Or
  • If of child bearing potential is willing to use a suitable and effective double barrier contraceptive method or intra uterine device during the study.
  • Urine pregnancy test (for female subjects*) must be negative at the time of screening. *No female subjects were enrolled in the study.

Exclusion Criteria:

  • Known hypersensitivity or idiosyncratic reaction to Paricalcitol or to any of its excipients or any drug or any substance.
  • History or presence of any disease or condition which might compromise the haemopoietic, renal, hepatic, endocrine, pulmonary, central nervous, cardiovascular, immunological, dermatological, gastrointestinal or any other body system.
  • Ingestion or Use of any medication at any time in 14 days prior to dosing. In any such case subject selection will be at the discretion of the Principal Investigator.
  • Any history or presence of asthma (including aspirin induced asthma) or nasal polyp or NSAID induced urticaria.
  • Consumption of Grapefruits or its products within a period of 48 hours prior to check-in.
  • A recent history of harmful use of alcohol(less than 2 years), i.e. alcohol consumption of more than 14 standard drinks per week for men and more than 7 standard drinks per week for women (A standard drink is defined as 360 ml of beer or 150 ml of wine or 45 ml of 40% distilled spirits, such as rum, whisky, brandy etc). " or consumption of alcohol or alcoholic products within 48 hous prior to check-in.
  • Smokers, who smoke 10 or more than 10 cigarettes / day or inability to abstain from smoking during the study.
  • The presence of clinically significant abnormal laboratory values during screening.
  • Use of any recreational drugs or history of drug addiction or testing positive in pre-study drug scans.
  • History or presence of psychiatric disorders.
  • A history of difficulty with donating blood.
  • Donation of blood (1 unit or 350 mL) or receipt of an investigational medicinal product or participation in a drug research study within a period of 90 days prior to the first dose of study medication. Elimination half-life of the study drug should be taken into consideration for inclusion of the subject in the study. Note: In case the blood loss is ≤ 200 mL, subject may be enrolled 60 days after blood donation or last sample of the previous study.
  • A positive hepatitis screen including hepatitis B surface antigen and anti- HCV antibodies.
  • A positive test result for anti-HIV antibody.
  • An unusual diet, for whatever reason (e.g. low-sodium), for four weeks prior to receiving the study drug and throughout the subjects' participation in the study. In any such case subject selection will be at the discretion of the Principal Investigator. Nursing mothers (females)*. *No female subjects were enrolled in the study.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02322632


Locations
Layout table for location information
India
Lambda Therapeutic Research Ltd
Ahmedabad, Gujarat, India, 3 80 061
Sponsors and Collaborators
Dr. Reddy's Laboratories Limited
Investigators
Layout table for investigator information
Principal Investigator: Dr. Pankaj Kumar Jha, MD Lambda Therapeutic Research Limited

Layout table for additonal information
Responsible Party: Dr. Reddy's Laboratories Limited
ClinicalTrials.gov Identifier: NCT02322632     History of Changes
Other Study ID Numbers: 280-01
First Posted: December 23, 2014    Key Record Dates
Last Update Posted: December 23, 2014
Last Verified: December 2014
Additional relevant MeSH terms:
Layout table for MeSH terms
Ergocalciferols
Calcium-Regulating Hormones and Agents
Physiological Effects of Drugs
Vitamins
Micronutrients
Nutrients
Growth Substances
Bone Density Conservation Agents